• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Zai Lab Ltd ADR (NQ: ZLAB )

    18.57 +0.57 (+3.17%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 671,820
    Open 18.12
    Bid (Size) 18.57 (1)
    Ask (Size) 19.25 (6)
    Prev. Close 18.00
    Today's Range 17.59 - 18.65
    52wk Range 13.48 - 32.59
    Shares Outstanding 956,637,360
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
    From Zai Lab Limited
    Via Business Wire
    Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga

    Performance

    YTD
    -28.74%
    -28.74%
    1 Month
    -7.89%
    -7.89%
    3 Month
    +14.77%
    +14.77%
    6 Month
    -26.60%
    -26.60%
    1 Year
    -28.55%
    -28.55%

    More News

    Read More
    Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
    From Zai Lab Limited
    Via Business Wire
    Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
    From Zai Lab Limited
    Via Business Wire
    Zai Lab Announces Participation in May and June Investor Conferences
    From Zai Lab Limited
    Via Business Wire
    Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
    From Zai Lab Limited
    Via Business Wire
    Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
    From Zai Lab Limited
    Via Business Wire
    Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
    Via FinancialNewsMedia
    Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    ZLAB Stock Earnings: Zai Lab Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
    From Zai Lab Limited
    Via Business Wire
    Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
    From Zai Lab Limited
    Via Business Wire
    Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
    From Zai Lab Limited
    Via Business Wire
    Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
    Via Talk Markets
    Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
    From Zai Lab Limited
    Via Business Wire
    One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
    Via Benzinga
    Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
    From Zai Lab Limited
    Via Business Wire
    Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
    From Zai Lab Limited
    Via Business Wire
    Shhh! 7 Small-Cap Stocks That Can Double by 2025
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.